Karyopharm Therapeutics Announces Nine Presentations On Its Selective Inhibitors Of Nuclear Export (SINE) Compounds And PAK4 Inhibitors At The American Association for Cancer Research Meeting

NATICK, Mass., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the presentation of seven posters covering its Selective Inhibitors of Nuclear Export (SINE) compounds and two posters covering its PAK4 inhibitors at the American Association of Cancer Research (AACR) meeting being held April 5-9, 2014 in San Diego, CA. Karyopharm's lead drug candidate, Selinexor (KPT-330), is a first-in-class, oral SINE compound that is undergoing Phase 1 studies in patients with advanced hematologic malignancies, solid tumors, and sarcomas. Karyopharm's allosteric PAK4 inhibitors are in preclinical development.

Help employers find you! Check out all the jobs and post your resume.